Dare Bioscience, Inc. current report, 18 July 2024

Filing summary

Company: Daré Bioscience, Inc. Filing: Form 8-K reporting events dated July 18, 2024; the press release was issued July 19, 2024.

Business context and key development

Daré is a biotechnology company developing therapies for women’s health. Nasdaq notified the company on July 18 that it had regained compliance with the $1.00 minimum bid-price requirement under Listing Rule 5550(a)(2), and that the matter was closed. Under a temporary exception, the stock’s closing bid had to be at least $1.00 for ten consecutive trading sessions before July 16, 2024.

Financial position

This 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, or other financial results. It provides no financial comparison with a prior period.

Outlook, regulatory matters, and risks

The company said it is continuing activities to advance Sildenafil Cream, 3.6%, toward Phase 3 pivotal studies for female sexual arousal disorder, for which it stated there are no FDA-approved treatments in the United States. Daré is awaiting further FDA feedback on proposed primary and secondary patient-reported outcome endpoints, data needed to qualify any non-sildenafil ingredient for vaginal administration in an NDA, and the size and duration of the safety database the FDA will require. The filing gives no timeline or assurance on resolution of these matters or progression to Phase 3.

Investor facts to verify

  • Nasdaq’s confirmation that the bid-price compliance matter is closed; the filing reports that notice was received July 18, 2024.
  • Any subsequent FDA feedback on the proposed endpoints, ingredient qualification data, and required safety database.
  • Any later updates on Phase 3 study plans, timing, and funding; none are specified in this filing.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.